ADG106 + PD-1 antibody

ADG106 + PD-1 antibody is a combination immunotherapy that pairs **ADG106**, a fully human ligand-blocking agonistic monoclonal IgG4 antibody targeting **CD137 (4-1BB)**, with a **PD-1 antibody** (such as pembrolizumab or toripalimab) in the treatment of advanced solid tumors and hematological malignancies. ADG106 activates CD137 to promote T cell proliferation, effector/memory T cell differentiation, and antitumor cytokine production (e.g., IFN-γ, TNFα, IL-6). **PD-1 antibodies** block the PD-1 immune checkpoint, reversing T cell exhaustion and potentiating immune responses against cancer. Combination therapy leverages synergistic immune stimulation, aiming to improve efficacy and overcome resistance seen with PD-1 inhibitors alone. Clinical studies have demonstrated manageable safety but limited efficacy, with ongoing research in advanced or metastatic cancers[1][3][4][5].

Brand names

KEYTRUDA (for pembrolizumab)toripalimab

Other names

ADG106 plus pembrolizumabADG-106 plus pembrolizumabADG 106 plus pembrolizumabADG106 plus toripalimabADG-106 plus toripalimabADG 106 plus toripalimabADG106 combined with anti-PD-1 antibodyADG-106 combined with anti-PD-1 antibodyADG 106 combined with anti-PD-1 antibody